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Background: Little is known about the factors associated with CT-quantified emphysema progression in heavy
smokers. The objective of this study was to investigate the effect of length of smoking cessation and clinical /
demographical factors on the rate of emphysema progression and FEV1-decline in male heavy smokers.
Methods: 3,670 male smokers with mean (SD) 40.8 (17.9) packyears underwent chest CT scans and pulmonary
function tests at baseline and after 1 and 3 years follow-up. Smoking status (quitted ≥5, ≥1-<5, <1 years or current
smoker) was noted. Rate of progression of emphysema and FEV1-decline after follow-up were assessed by analysis
of variance adjusting for age, height, baseline pulmonary function and emphysema severity, packyears, years in
study and respiratory symptoms. The quitted ≥5 group was used as reference.
Results: Median (Q1-Q3) emphysema severity,<-950 HU, was 8.8 (5.1 – 14.1) and mean (SD) FEV1 was 3.4 (0.73) L or
98.5 (18.5) % of predicted. The group quitted ‘>5 years’ showed significantly lower rates of progression of
emphysema compared to current smokers, 1.07% and 1.12% per year, respectively (p<0.001). Current smokers had a
yearly FEV1-decline of 69 ml, while subjects quit smoking >5 years had a yearly decline of 57.5 ml (p<0.001).
Conclusion: Quit smoking >5 years significantly slows the rate of emphysema progression and lung function
decline.
Trial registration: Registered at www.trialregister.nl with trial number ISRCTN63545820.
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Chronic obstructive pulmonary disease (COPD) is a
common pulmonary disease with an estimated preva-
lence of 8.9% worldwide [1]. Currently it is already one
of the major causes of mortality and will become the
third cause by 2020 [2]. COPD hallmarks are the accel-
erated lung function decline and emphysema progres-
sion. It is known that smoking cessation results in
diminishing, but not in a total disappearance of inflam-
mation and in dampening of the accelerated lung
function decline [3-5]. Such is also expected for the em-
physema progression over time, however few longitudinal
studies in smokers have been performed studying emphy-
sema progression [6].* Correspondence: fmohamedhoesein@gmail.com
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distribution, and reproduction in any mediumRegarding emphysema progression in smokers, Suki
et al. launched the hypothesis that the smoking related
inflammation is not the only culprit, and that mechan-
ical factors also play a role [7]. These mechanical factors
are believed to be the start of an unstoppable cascade of
increasing tissue destruction. A recent editorial addressed
this as an important step in the understanding of emphy-
sema progression [8]. Therefore, if inflammation is the
only cause of emphysema progression this should be a
function of the length of smoking cessation: none to min-
imal in subjects who stopped smoking a long time ago and
strong in current smokers.
At a cross-sectional level it has been reported that CT-
quantified emphysema is associated with demographical
and clinical factors and an increasing number of studies
report on effects of smoking habits on CT-quantified
emphysema at a cross-sectional level [9-11]. However, there
is little knowledge on the demographical and clinical factorsed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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relatively healthy smokers.
The Dutch-Belgium lung cancer screening trial in-
cluded a large number of relatively healthy, but heavy
current and former smoking subjects, at risk for devel-
oping COPD [12]. A considerable fraction of these
smokers stopped their habit and in this cohort we in-
vestigated the effect of the length of smoking cessation
and secondarily some clinical / demographical factors
on emphysema progression and lung function decline.Methods
Participants
The included subjects were part of a lung cancer screen-
ing trial, the NELSON trial [12,13]. Male subjects,
meeting the inclusion criterion of having smoked ≥20
packyears, were randomly sampled from the general
population. Subjects should not have quit smoking more
than 10 years before inclusion. Baseline details on smok-
ing habits were gathered through questionnaires which
included questions about duration of smoking, number
of cigarettes smoked a day and, if applicable, the dur-
ation of smoking cessation at enrolment of the study
(≥5 years, ≥1 - <5 years, <1 year and current smoker).
Self-reported respiratory symptoms (cough, mucus,Participants who unde
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Figure 1 Flowchart of included subjects.dyspnea and wheezing) were also collected via ques-
tionnaires at baseline.
A chest CT scan was performed at least three times in
all subjects: year 0 (at start study), year 1 and year 3. In
addition, in a number of subjects ‘in between’ scans were
made for follow-up of suspect nodules to exclude growth
of these nodules which were also included. All included
subjects underwent pulmonary function testing (PFT) at
baseline. A random sample of approximately two out of
three also underwent follow-up (PFT), see Figure 1.
The NELSON trial was approved by the Dutch Ministry
of Health and by the institutional review boards of the par-
ticipating centres. The NELSON trial is registered at www.
trialregister.nl (trial number ISRCTN63545820). Written
informed consent was obtained from all subjects.
CT Scanning and quantification of emphysema
The CT protocol has been described in detail before and
a more detailed description is also reported in the
Additional file 1 [13-15]. In short, all participants re-
ceived low-dose CT during full inspiration. No spiromet-
ric gating was applied. There were no significant
differences in CT derived inspiratory volume between
the baseline and follow-up scans. Exposure settings were
30mAs at 120kVp or 140kVp. This low-dose CT proto-
col has previously been used to quantify emphysema inSubjects enrolled 
(N=3,670)  
rwent 
w-up 
sting  
articipants included 
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were automatically analyzed [16]. CT examinations were
recalibrated using air in the trachea to ensure compar-
ability between the two centers. Quality control was
done by scanning a phantom before and after scan ses-
sions. The phantom was scanned before and after each
date acquisition session to see if the range of HU values
was in the range of that specified by the vendor and to
determine systematic deviations. During the trial no sys-
tematic deviations in HU value occurred. Emphysema
quantification was based on the -950 HU and -910 HU
technique: this method delivers the percentage lung
volume with a density <-950 HU or <-910 HU. As sec-
ondary parameters the 15th percentile technique was
used: providing the cut off value in Hounsfield units
(HU) below which 15% of all voxels are distributed [17].
Pulmonary function tests
Pulmonary function tests (PFT) were performed in year 0
and 3 with standardized equipment according to American
Thoracic Society guidelines including FEV1 and FEV1/
forced vital capacity (FVC) [18]. Bronchodilatation was
not applied. Baseline FEV1/FVC and FEV1 served
to assess whether airflow obstruction was present
(if FEV1/FVC <70%) and to determine the baseline
GOLD stage [19].
Statistical analysis
Mean and standard deviation (SD) values were calcu-
lated for normally distributed data and median values
and inter quartile range (Q1-Q3) for non-normally dis-
tributed data. Distribution of normality was checked
visually by Q-Q plots.
Baseline data were evaluated using analysis of variance
or χ [2]-test, where appropriate. For these longitudinal
data a linear mixed model (a random intercept, random
slope variant with an unstructured covariance matrix)
was used. Linear mixed modeling results in a linear re-
gression equation with (amongst others) time as an ex-
planatory parameter, while correcting for the correlation
between observations. The period of observation since
the start of the study per subject was the time factor in
this analysis.
The variable of interest was the ‘percentage lung vol-
ume <-950 HU’ and as this is a log-normal distributed
parameter we applied a log (ln) transformation first.
Smoking status at enrolment of the study (quitted ≥5
years, ≥1 - <5 years, <1 year or current smoker) was the
main explanatory factor. To assess whether the progres-
sion of emphysema differed between these smoking
groups, the interaction between the smoking status and
‘time of observation’ was the next relevant factor. The
quitted ≥5 years group was used as a reference. We ad-
justed for presence of respiratory symptoms (cough,wheezing, dyspnea and /or mucus), packyears of smok-
ing, baseline GOLD stage, study center, height and age
at start study. The FEV1 decline was analyzed in the
same way as the emphysema progression. P-values ≤0.05
were considered significant. Statistical analyses were
performed via SPSS20 (Chicago, USA).
Results
Baseline demographics and lung function results
Baseline demographics and lung function test outcomes
are shown in Table 1. In total 3,670 male subjects of
middle age (~60 years) were included. All were current
(n= 1,614) or former heavy (n=2,056) smokers with a
mean (SD) packyears of 40.8 (17.9). The majority of
these subjects, 2,403 (65%), had an FEV1/FVC >70%, but
there were no differences in airflow obstruction preva-
lence between the four smoking groups (p= 0.233). Also
no significant differences in FEV1 and FEV1/FVC were
present between the four smoking groups (p= 0.415 and
p=0.185, respectively). Of the 3,670 subjects included a
random sample of 2,220 also underwent follow-up pul-
monary function testing, see Figure 1. Current smokers
significantly had more respiratory complaints (Table 1).
Baseline emphysema
The effect of the significant parameters on % lung vol-
ume <-950 HU are given in Table 2. Current smokers
had less emphysema at baseline compared to the long
term quitters. This contra-intuitive phenomenon has
been described earlier and is believed to mirror the
presence of inflammation in smokers, which thickens
the mucosa and increases tissue density [20]. Subjects
with the lowest GOLD stage showed less emphysema
severity compared to those with the highest GOLD stage
(p=0.013). Respiratory symptoms had no significant
effect on baseline emphysema. Similar results were
found for the <-910 HU and for the Perc15 (Additional
file 1: Table S1).
Effects on rate of emphysema progression
The median (Q1-Q3) time of observation was 3.0
(2.9 – 3.1) years. All factors in the model significantly
influenced (all p<0.001) the severity of emphysema,
except for study center (p=0.619).
Table 3 lists the results from the linear mixed model.
The annual emphysema increase for all subjects (irrespect-
ive of smoking status) was highly significant (p<0.001) and
was 1.07% of the total lung volume per year. For instance,
a subject with a -950 HU value of 8.8%, being the mean
value of the cohort, will show a -950 HU value of 9.1%
after three years.
The interaction between ‘smoking group’ and ‘observa-
tion time’ indicates that the development of emphysema
differed between these groups (p<0.001). Only the current
Table 1 Baseline demographics for the total cohort and split by smoking status
Total n = 3,670 Current smoker
n= 2,056
Quitted <1 year
n=284
Quitted ≥1 – <5 years
n=711
Quitted ≥5years
n=619
Age 59.8 (5.4) 58.9 (4.9) 59.8 (5.3) 60.4 (5.5) 62.1 (6.2)
height (cm) 178 (7) 178 (7) 179 (7) 178 (7) 177 (7)
FEV1/FVC 72.2 (9.4) 72.8 (9) 72.8 (9.1) 71.8 (10.2) 71.9 (9.4)
FEV1 [L] 3.4 (0.73) 3.4 (0.8) 3.4 (0.7) 3.5 (0.8) 3.4 (0.7)
FEV1 [%] 98.5 (18.5) 99.9 (20) 100 (18) 97.1 (19.4) 97.6 (17.9)
Packyears 40.8 (17.9) 40.0 (16.4) 41.0 (17.5) 43.1 (20.2) 40.6 (19.5)
observation time (years)* 3.0 (2.9 – 3.1) 3.0 (2.9-3.1) 3.0 (2.9-3.1) 3.0 (2.9-3.1) 3.0 (2.9-3.1)
GOLD classification
normal (%) 65.5 63.2 65.5 68.8 69.1
stage I (%) 22.0 23.4 20.4 20.8 19.2
stage II (%) 10.9 11.6 12.0 9.1 10.3
stage III (%) 1.6 1.8 2.1 1.3 1.5
stage IV (%) 0.1 0.1 0 0 0
Presence of respiratory
symptoms
cough (%) 32.0 46.0 24.9 14.5 10.7
wheezing (%) 23.8 33.0 20.9 13.1 7.4
dyspnea (%) 29.5 34.4 29.5 23.3 20.8
mucus (%) 30.0 39.6 26.0 17.8 15.2
lung volume <-950 HU (%)* 8.8 (5.1 – 14.1) 6.8 (3.9 – 11.5) 10.5 (6.7 – 15.2) 11.3 (7.4 – 17.2) 11.9 (7.5 – 16.9)
lung volume <-910 HU (%)* 35.2 (24.1 – 46.0) 30.2 (20.1 – 41.9) 38.4 (28.7 – 47.9) 40.9 (30.6 – 50.7) 41.2 (31.6 – 51.4)
perc15 (HU) −935 (19) −930 (21) −939 (16) −942 (18) −942 (17)
Mean and standard deviation (SD) is provided*median (Q25 – Q75).
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quitters) (p<0.001): the additional yearly increase per year
is 1.05 (see Table 3, observation time * smoking group). So
a current smoker faces a total emphysema increase of
1.12% per year, see Figure 2. The analysis could not show
that the <1 year and ≥1 - <5 years quitters differed signifi-
cantly from the ≥5 years quitters in additional decline
(p=0.799 and p=0.234): these two groups seem to suffer
from a similar yearly emphysema increase. The effect of
aging was estimated as a 1.02% increase per year: for each
year a subject gets older, the %<-950 increases with 1.02%.
Table 3 lists the results from the linear mixed model.
No association with respiratory symptoms was found.
Similar results were found for <-910 HU and Perc15
(Additional file 1).
Effects on FEV1-decline
The mixed model analysis showed that all investigated
factors significantly influenced the level of FEV1-decline
(all p<0.001). The annual FEV1 decline for all subjects
(irrespective of smoking status) was 57.5 ml/year
(p<0.001, see Table 4). The interaction between ‘smoking
group’ and the ‘observation time’ was highly significant
(p<0.001) indicating that the FEV1 decline differed be-
tween the groups. Current smokers differed significantlyfrom the reference group (= ≥5 years quitters), with an
additional yearly decline per of 11.5 ml (p<0.029). So
current smokers faced a total FEV1 decline of 69 ml/
year (57.5 ml + 11.5 ml), see Figure 3. The analysis
furthermore showed that the <1 year quitters differed
significantly from the ≥5 years quitters in additional de-
cline (p=0.019), but not from the ≥1 - <5 years quitters
(p=0.237). The effect of normal aging is estimated to be
a decrease of 29 ml per year [21].
Correlation between emphysema progression and lung
function decline
The FEV1-decline was not significantly correlated to
the emphysema progression over the observation time
(R= 0.004675; p= 0.826).
Discussion
The results show that in this large cohort of heavy
current and former smokers, the progression of emphy-
sema was lower in >5 years quitters compared to current
smokers. The FEV1 decline reduced with increasingly
longer stopped smoking duration. However, even in
long-term quitters the lung function decline was higher
as expected compared to normal lung function decline.
Although we found a significant effect of smoking
Table 2 Effect estimates of listed parameters on baseline
% lung volume <-950 HU values
Parameter Effect size p-value. 95% CI of
effect size
Lower
bound
Upper
bound
Center
UMCU 0.87 <0.001 0.83 0.91
UMCG (reference)
smoking group
current smoker 0.60 <0.001 0.56 0.64
quitted <1 year 0.90 0.033 0.81 0.99
quitted ≥1 – <5 years 0.99 0.956 0.93 0.99
quitted ≥5years
(reference)
baseline GOLD stage
normal 0.17 0.013 0.04 0.68
stage I 0.26 0.065 0.06 1.08
stage II 0.29 0.089 0.07 1.21
stage III 0.46 0.279 0.11 1.89
stage IV (reference)
Presence of respiratory
symptoms
cough 0.87 0.980 0.82 0.91
wheezing 0.97 0.449 0.90 1.05
dyspnea 1.00 0.786 0.94 1.08
mucus 1.02 0.568 0.95 1.09
height (cm) 1.01 <0.001 1.01 1.02
age at start study
(years)
1.02 <0.001 1.01 1.02
packyears 0.99 <0.001 0.99 1.00
The column headed with ‘effect size’ gives the change in % lung volume <-950
HU due to a unit change in the parameter or due to membership of another
class. So for each year a subject is older at the start of the study, the % lung
volume <-950 HU increases with a factor or1.02 per year. For class comparisons
the changes are versus the reference group: so a subject with an FEV1/FVC >70%
(no COPD) has 0.17 times lower % lung volume <-950 HU compared to the
reference GOLD class 4 (the p-value for this comparison is <0.001).
Table 3 Effect estimates of listed parameters on the
increase of the % lung volume <-950 HU values
Parameter Effect size p-value. 95% CI of
effect size
Lower
bound
Upper
bound
center
UMCU 1.01 0.619 0.97 1.05
UMCG (reference)
smoking group
current smoker 0.60 <0.001 0.56 0.64
quitted <1 year 0.91 0.083 0.82 1.01
quitted ≥1 – <5 years 0.99 0.868 0.92 1.07
quitted ≥5years
(reference)
baseline GOLD stage
normal 0.18 0.002 0.06 0.54
stage I 0.28 0.022 0.09 0.83
stage II 0.31 0.040 0.10 0.95
stage III 0.47 0.183 0.15 1.43
stage IV (reference)
height (cm) 1.01 <0.001 1.07 1.01
Presence of respiratory
symptoms
cough 0.96 0.647 0.93 1.05
wheezing 1.01 0.881 0.94 1.07
dyspnea 0.99 0.773 0.94 1.05
mucus 1.02 0.724 0.96 1.09
age at start study
(years)
1.02 <0.001 1.01 1.02
packyears 0.99 <0.001 0.97 0.99
observation time 1.07 <0.001 1.06 1.09
observation time *
smoking group
current smoker 1.05 <0.001 1.03 1.07
quitted <1 year 0.99 0.799 0.97 1.02
quitted ≥1 – <5 years 0.99 0.234 0.97 1.01
quitted ≥5years
(reference)
The column headed with ‘effect size’ again contains the change in % lung
volume <-950 HU due to a unit change in the parameter or due to membership
of another class. For instance, for each year a subject is older at the start of the
study, the % lung volume <-950 HU increases with a factor of 1.02. For class
comparisons the changes are versus the reference group: so a subject with an
FEV1/FVC >70% (no COPD) has a 0.18 times lower lung volume <-950 HU
compared to the reference GOLD class 4 (the p-value for this comparison is
0.002). The parameter observation time denotes the annual change in % lung
volume <-950 HU being times 1.07 higher per year.
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fect was not as high as we expected or hoped for. Our
data thus seem to confirm the hypothesis of Suki et al
who proposed that the initial inflammation is believed to
permanently damage / weaken the collagen fibers with
subsequent mechanical failure [7]. It could well be that
mechanical factors play an important role in starting an
unstoppable cascade of tissue destruction not stopped
by long term smoking cessation resulting in ongoing
progression of emphysema in heavy smokers. Indeed, al
included participants were heavy smokers with mean
packyears smoked of 40 years.
The effect of smoking cessation on emphysema pro-
gression and lung function decline differ, i.e. there was a
larger effect on lung function. It may be that reduction
of emphysema progression takes more time. Smokingrelated inflammation should have dampened during our
long non-smoking follow-up period of 5 years. After
smoking cessation, the pathological processes leading to
the accelerated FEV1-decline need some time to dimin-
ish. A large study in male UK doctors reported it
took ~1 year before all COPD-related mortality rates
Figure 2 Graph showing the increase of emphysema (% lung
volume below -950 HU) in two men, age 60 at the start of the
observation (t=0) with 40 packyears smoked in GOLD stage 1
(height 175 cm). One is a current smoker, the other a >5 year
quitter. For sake of clarity the other two smoking groups were
omitted from this graph as their emphysema increase is within
these extreme groups.
Table 4 Effect estimates of listed parameters on the
longitudinal FEV1 (milliliters) values
Parameter Effect size p-value. 95% CI of
effect size
Lower
bound
Upper
bound
center
UMCU -.74.4 <0.001 −103 46
UMCG (reference)
smoking group
current smoker −101 <0.001 −142 −61
quitted <1 year −68 0.033 −130 −5
quitted ≥1 – <5 years −32 0.188 −80 15
quitted ≥5years
(reference)
baseline GOLD stage
normal 2346 <0.001 1497 3195
stage I 2035 <0.001 1185 2884
stage II 1187 0.006 337 2037
stage III 346 0.428 −510 1202
stage IV (reference)
height (cm) 044 <0.001 41 46
Presence of respiratory
symptoms
cough −11 0.607 −7 19
wheezing −106 <0.001 −152 −60
dyspnea −76 <0.001 −117 −34.7
mucus 12 0.580 −30 54
age at start study
(years)
−29 <0.001 −32 −27
packyears −3.2 <0.001 −4 −2
observation time −58 <0.001 −66 −48
observation time *
smoking group
current smoker −12 0.029 −22 −1
quitted <1 year −19 0.019 −35 −3
quitted ≥1 – <5 years 0.8 0.237 −5 20
quitted ≥5years
(reference)
The column headed with ‘effect size’ contains the change in FEV1 (millliters)
due to a unit change in the parameter or due to membership of another class.
So for each year a subject is older at the start of the study the FEV1 decreases
with 29 millliters.
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crease in the blood and bronchoalveolar lavage fluid
leukocyte levels after nine months of smoking cessation,
when compared to never smokers [23,24]. Together,
these results indicate that the increased inflammation
should be halted during the 5 years non-smoking period
of the former smokers.
Only a few other studies longitudinally examined the
effect of smoking status on emphysema progression.
Bellomi et al. found that, after 2 year of follow-up,
current smokers showed significantly stronger emphy-
sema progression than former smokers [6]. The design
of the study was comparable to ours: subjects partici-
pated in a lung cancer screening trial and underwent
low-dose CT. However, no lung function was obtained
and it may not be unlikely that significant differences in
FEV1/FVC and FEV1 values existed between the former
and current smokers. Furthermore, they did not take the
length of smoking cessation into account. Soejima et al.
found no significant differences in emphysema progres-
sion between former and current smokers after a five
year follow-up [25]. A drawback is that the number of
subjects included was very small, 35 current smokers
and 12 past smokers, which could have lead to a lack of
power. A recent study by Coxson et al. is of special
interest as they also studied emphysema progression
assessed by CT, but in a more severe population as ours
[26]. They studied 1,928 male and female subjects with
COPD stage II-IV and found that emphysema progres-
sion was more severe in current smokers and in females.
These findings are in line with our findings, but arecomplementary as we included heavy smokers without
or only mild COPD.
Our results expand / confirm the outcome of e.g. the
Lung Health Study (LHS), a study investigating the effect
of smoking cessation in COPD subjects which found
that quitters had a considerably lower FEV1 decline than
continuous smokers [27]. The average yearly FEV1 de-
cline was 62 ml in continuous smokers, and 31 ml in
quitters. In our cohort this was slightly higher, namely
69 and 57.5 ml/ year, respectively. There are some
Figure 3 Graph showing the decrease of FEV1 in two men,
age 60 at the start of the observation (t=0) with 40 packyears
smoked in GOLD stage 1 (height 175 cm). One is a current
smoker, the other a >5 year quitter. For sake of clarity the other two
smoking groups were omitted from this graph as their FEV1 decrease.
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Firstly, the LHS included subjects with COPD, while the
vast majority of our subjects had no COPD. The popula-
tion studied in the LHS was relatively young, with a
mean age below 50 years, but with the same exposure to
tobacco as our population (~40 packyears). The LHS
thus included younger smokers with an apparent in-
creased COPD susceptibility.
As expected we found the tissue density in ex-smokers
to be lower compared to current smokers [20]. This is
probably caused by the presence of inflammation and
mucus which influences emphysema quantification by
raising the density of the lungs. In the long-term quitters
inflammation and mucus production will have disappeared
before the observation period started and changes over
time cannot be influenced by it. In current smokers the
inflammation and mucus production increased density,
but as long as this is constant it is not an influencing
factor for changes over time. A further increase in density
(via an increased smoking burden) would again reduce the
emphysema progression, as found on CT. Another explan-
ation could be the so-called healthy smoker effect in which
smokers with little respiratory complaints keep smoking
while subjects who have respiratory complaints stop at an
early stage.
A positive point of our study is that we included a
large sample of heavy smoking subjects selected from
the general population and at risk to the develop COPD,
rendering our results applicable to the vast number of
so-called ‘healthy smokers’. Especially this group is of
interest because smoking cessation is the most effective
intervention and may prevent progression to COPD.
Secondly, emphysema was quantified fully automatic bysoft-ware packages, free from inter- and intra-observer
variability.
This study also has some limitations. Firstly, smoking
cessation was self-reported. Some subjects could have
restarted smoking during the observation period; how-
ever this only would dilute the reported effects of the
length of smoking cessation. So we expect to underesti-
mate true effects. Secondly, no females were included in
our study: previous research showed that females benefit
more from smoking cessation which may imply that
women may have less emphysema progression after
smoking cessation [28,29]. It is not expected that em-
physema progression will be less in women, but it at the
least will be similar or larger compared to men. Female
sex may also be a risk factor for an increased emphy-
sema progression [26,30]. Future studies should include
females to elucidate this. It has been reported that in-
spirational levels affect the quantification of emphysema
at CT. Thirdly, one of the limitations of the quantitative
analysis of low attenuation voxels at CT is that other
conditions, like for instance mucus in the airways or
atelectasis, are not incorporated in the single emphy-
sema measurement. To our knowledge, this is inevitable
with the current soft-ware and quantification methods.
Ideally, one may spirometrically gate the CT scans to
ensure that repeat CT scans are acquired at the same in-
spirational level. However, this is not feasible in large
multi-center studies. In our study we inserted all the in-
dividual inspirational levels in the analyses and found
that they did not influence the outcomes (data not
reported). A last issue might be that we cannot assess
the effects of the increasing emphysema severity on e.g.
diffusing capacity and static lung volumes, as these were
not part of this longitudinal study.
In conclusion, we have showed that smoking cessation
for ≥5 years decreased lung function decline when com-
pared with current smokers. However, the effect was not
as high as expected giving support to the hypothesis that
long term smoking starts a unstoppable cascade of tissue
damaging. Nonetheless, our results emphasize on the
benefits of smoking cessation, regardless of being a
heavy smoker.
Additional file
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